Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
MNRO vs ECX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MNRO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–4 Matrix Metrics)
MNRO Overall Winner
6-Pillar Tally: MNRO 6 – 0 ECX
Matrix Metrics: MNRO 6 – 4 ECX
As of Nov 19, 2026, Monro, Inc. (MNRO) is the stronger overall head-to-head candidate over ECARX Holdings Inc. Class A (ECX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MNRO carries a Unified Composite Score of 49.6/100 (HOLD) at $9.76 (53.8x Forward P/E, 1.2% operating margin), whereas ECX carries 52.4/100 (HOLD) at $0.69 (12.1x Forward P/E, -4.6% operating margin).
- Composite vs. Pillar Nuance: While ECX currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. MNRO 49.6/100 HOLD), MNRO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (1.2% vs. -4.6% operating margin) and revenue trajectory (-1.8% vs. +9.5% YoY).
- Technical & Structure Timing Caution: MNRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9); meanwhile ECX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MNRO vs ECX
MNRO
Head-to-Head Winner
Monro, Inc. Common Stock
$9.76
-4.69% 1D
Market Cap
$320.8M
TTM Revenue
$1.14B
Forward P/E
53.8x
Beta / 30D Vol
2.06β · 78% Vol
Unified Composite Score
49.6
HOLD
Tech 53.0
Fund 64.0
Flow 55.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
ECX
ECARX Holdings Inc. Class A Ordinary shares
$0.69
-9.78% 1D
Market Cap
$300.6M
TTM Revenue
$902M
Forward P/E
12.1x
Beta / 30D Vol
0.44β · 122% Vol
Unified Composite Score
52.4
HOLD
Tech 50.0
Fund 53.0
Flow 50.0
Mom 68.9
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MNRO 6 – 0 ECX)
1. Valuation Multiples
MNRO
Forward P/E
53.8x
12.1x
Trailing P/E
53.8x
N/M
PEG Ratio
3.59x
N/M
EV / Revenue
0.7x
0.8x
2. Growth & Scale
MNRO
Revenue Growth (YoY)
-1.8%
+9.5%
Earnings Growth (YoY)
+161.3%
+0.0%
TTM Revenue (USD)
$1.14B
$902M
Market Cap
$320.8M
$300.6M
3. Profitability & Quality
MNRO
Gross Margin
34.8%
15.3%
Operating Margin
1.2%
-4.6%
Net Profit Margin
0.1%
-7.4%
Return on Equity (ROE)
0.1%
-2237.6%
4. Balance Sheet & Cash Flow
MNRO
Cash Generation (TTM)
$12M
-$22M EBITDA
Cash Flow Margin
1.1%
-2.4% EBITDA Mgn
Net Cash / Leverage
$492M Net Debt (0.88x D/E)
$466M Net Debt
Dividend Yield
11.12%
None (0.00%)
5. Options & Positioning
MNRO
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
77.3% (11th %ile)
N/A (N/A)
Put/Call OI Skew
0.05x (Call-Skewed)
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
MNRO
OpEx & R&D Intensity
33.6% of Rev ($382M)
19.9% of Rev ($180M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Auto Parts Operator
Auto Parts Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MNRO (6) vs ECX (4)| Institutional Metric | MNRO | ECX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $320.8M | $300.6M | MNRO | |
| Trailing P/E Ratio | 53.8x | N/M | MNRO | |
| Forward P/E Ratio | 53.8x | 12.1x | ECX | |
| Revenue Growth (YoY) | -1.8% | +9.5% | ECX | |
| Operating Margin (TTM) | 1.2% | -4.6% | MNRO | |
| Net Profit Margin | 0.1% | -7.4% | MNRO | |
| Return on Equity (ROE) | 0.1% | -2237.6% | MNRO | |
| 52-Week Range Position | 0% ($10–$24) | 1% ($1–$2) | ECX | |
| Beta / 30D Volatility | 2.06β · 78% Vol | 0.44β · 122% Vol | MNRO | |
| Unified Institutional Score | 49.6 / 100 (HOLD) | 52.4 / 100 (HOLD) | ECX | |
| Trailing 12M Revenue (USD) | $1.14B | $902M | Scale | |
| Gross Profit Margin (TTM) | 34.8% | 15.3% | Quality | |
| PEG Ratio & EV / Revenue | 3.59x PEG · 0.7x EV/Rev | N/M PEG · 0.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $12M ($492M Net Debt (0.88x D/E)) | -$22M EBITDA ($466M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ECX +8.78 pp
3M Horizon
MNRO +14.45 pp
6M Horizon
ECX +8.76 pp
1Y Horizon
MNRO +17.87 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MNRO Revenue | ECX Revenue | MNRO Op. Margin | ECX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $1.20B | N/A | 10.6% | N/A | MNRO |
| FY2020 | $1.26B | N/A | 8.1% | N/A | MNRO |
| FY2021 | $1.13B | N/A | 6.4% | N/A | MNRO |
| FY2022 | $1.36B | $520M | 7.5% | -41.2% | MNRO |
| FY2023 | $1.33B | $660M | 6.0% | -19.6% | MNRO |
| FY2024 | $1.28B | $770M | 5.6% | -15.9% | MNRO |
| FY2025 | $1.20B | $850M | 1.1% | -6.5% | MNRO |
| FY2026 | $1.16B | N/A | 1.7% | N/A | MNRO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MNRO
BREAKDOWN
Current IV
77.3%
IV Percentile
11th %ile
Put/Call OI Skew
0.05x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact MNRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ECX
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ECX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MNRO Moat Profile
Cyclical / Execution-Driven Positioning
Auto Parts Operator
OpEx & R&D Reinvestment
33.6% of Rev ($382M)
90D Engineering Disclosures
0 Published
ECX Moat Profile
Cyclical / Execution-Driven Positioning
Auto Parts Operator
OpEx & R&D Reinvestment
19.9% of Rev ($180M)
90D Engineering Disclosures
0 Published
Investor FAQ MNRO vs ECX Key Questions & Quantitative Answers
As of Nov 19, 2026, Monro, Inc. (MNRO) is the stronger overall head-to-head candidate over ECARX Holdings Inc. Class A (ECX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MNRO carries a Unified Composite Score of 49.6/100 (HOLD) at $9.76 (53.8x Forward P/E, 1.2% operating margin), whereas ECX carries 52.4/100 (HOLD) at $0.69 (12.1x Forward P/E, -4.6% operating margin). Composite vs. Pillar Nuance: While ECX currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. MNRO 49.6/100 HOLD), MNRO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (1.2% vs. -4.6% operating margin) and revenue trajectory (-1.8% vs. +9.5% YoY). Technical & Structure Timing Caution: MNRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9); meanwhile ECX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MNRO leads the Growth & Scale pillar: MNRO posts -1.8% YoY revenue growth and +161.3% YoY earnings growth on $1.14B TTM revenue (34.8% gross margin, 1.2% operating margin), compared with ECX at +9.5% YoY revenue growth and +0.0% YoY earnings growth on $902M TTM revenue (15.3% gross margin, -4.6% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), MNRO cumulative revenue shifted -3.3% while ECX shifted +63.5%. In operating R&D and SG&A reinvestment, MNRO deploys 33.6% of Rev ($382M) (0 90-day corporate R&D disclosures) versus 19.9% of Rev ($180M) (0 disclosures) for ECX.
MNRO screens cheaper on headline valuation multiples. MNRO trades at 53.8x Forward P/E, 53.8x Trailing P/E, 3.59x PEG, and 0.7x EV/Revenue (1.1% FCF margin), whereas ECX trades at 12.1x Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-2.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNRO (0.1% ROE) versus ECX (-2237.6% ROE) capital efficiency.
In options market volatility and institutional positioning, MNRO carries 77.3% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.06β · 78% Vol realized risk). By comparison, ECX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 122% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ECX vs MNRO · Reverse Pair
MNRO vs DORM
· Sector Peer
MNRO vs JJSF
· Sector Peer
MNRO vs MATW
· Sector Peer
ECX vs SFWL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma